Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (390)	3/15/1999 7:27:00 PM
From: Edscharp	Read Replies (2) \| Respond to of 712

FYI - From the Medical Technology Stock Letter dated March 11, 1999 "One of the most obvious acquisition candidates is Cor Therapeutics. They have a product on the market, they are moving rapidly toward profitability, and their focus on cardiovascular disease is attractive to a company like Chiron, which has made a commitment to this sector. It is also worth noting that Chiron's Chief Scientific Officer, Rusty Williams, was the scientific founder of Cor. Once the stock gets moving so that Chiron would consider a reasonable premium over market, it is one of the most likely merger targets. Other companies among our recommended stocks which are particularly attractive merger targets are Onyx, ImmunoGen, Celtrix and maybe Imclone Systems." .....In addition, Wall Street does not understand the huge potential of not only Integrilin, which is already approved, but of their oral anti-platelet drug, which could be another big product, and which has yet to be partnered. We cannot find words strong enough to tell you how much we love the stock at these prices. Corr is a buy under $18.